Effect of clomiphene citrate upon amount and duration of human menopausal gonadotropin therapy.
Human menopausal gonadotropin (HMG) was given to 10 patients who failed to ovulate after treatment with clomiphene citrate. Prior to one or more treatment courses, 200 mg. of clomiphene were administered daily for 5 days; at least one other treatment course was not preceded by clomiphene. Before therapy, progesterone in oil was administered and serum FSH, LH, and estrogen were measured. Those patients who had normal serum FSH levels and had withdrawal bleeding following progesterone had a reduction in amount and duration of HMG requirements for those patients with low serum FSH who did not withdraw. Thus, sequential clomiphene-HMG therapy is of benefit only for those women with normal serum FSH levels and is the treatment of choice.
D000328:Adult; D000858:Anovulation / Q000150:complications / Q000188:drug therapy*; D002996:Clomiphene / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy / Q000209:etiology; D007986:Luteinizing Hormone / Q000097:blood; D008596:Menotropins / Q000627:therapeutic use*
D004967:Estrogens; D002996:Clomiphene; D008596:Menotropins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone